Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Potential Breakthrough for Many Common Cancers


Published on

Published in: Health & Medicine
  • Be the first to comment

Potential Breakthrough for Many Common Cancers

  1. 1. June 11, 2013COTI-2 | A Potential BreakthroughTherapy for Many Cancers
  2. 2. 2TSXV: COTAbout COTI-2Late preclinicaldrug candidatediscovered usingCHEMSAS®- the company’s proprietary,artificial intelligence-baseddrug discovery technology2TSXV: COT
  3. 3. 3TSXV: COTCOTI-2 highlights123Potential breakthrough therapy formany cancersActive against many cancers withmutations of the p53 gene> 50% of all human cancers have a p53mutation
  4. 4. 4TSXV: COTWhy p53 is important?p53 is a tumoursuppressinggeneA mutation of the p53 gene is the most commonmutation found in human cancer cellsIf mutated, cancerscan develop & growwithout control
  5. 5. 5TSXV: COTThe future of cancer treatmentsCOTI-2 wouldtreat geneticmutationscommon in manytypes of cancerMost current treatmentsare organ specific(i.e. treatment for lung cancer,colon cancer, etc.)COTI-2 targets andprimarily destroystumor cellsBy way of contrast,traditional chemotherapykills growing & dividingcells, cancer or healthy
  6. 6. 6TSXV: COTCOTI-2 development progressEasily synthesized oral formulation with nostability issuesEffective alone or in combination with approvedcancer drugsIn final two-species toxicity studies prior to FDAfiling in late 2013 enabling human trials
  7. 7. 7TSXV: COT4 U.S. patents granted – strengthening COTI-2’s valuepropositiono Composition of matter protection to 2030Patents pending in USA, Europe, Canada and JapanPatent strategy preserves downstream patent filingopportunities for potential extension of marketexclusivityWe own all intellectual property with no licenseobligationsCOTI-2 intellectual property overview
  8. 8. 8TSXV: COTTSXV: COTWhy license COTI-2?Drug development is a long and expensive processOur core competence is accelerating drugdiscovery, not drug developmentRecent preclinical oncology licensing dealsincluded:o Upfront payments of approx. $5-$15 milliono Milestone payments between $120-$288 milliono Royalties on net sales
  9. 9. 9TSXV: COTWhen used anywhere in this presentation, whether oral or written, the words potential,expects, believes, anticipates, estimates and similar expressions are intended to identifyforward-looking statements. Forward-looking statements may include statementsaddressing future financial and operating results of Critical Outcome Technologies Inc.(COTI).COTI bases these forward-looking statements on its current expectations about futureevents. Such statements are subject to risks and uncertainties including, but not limited to,the successful implementation of COTI’s strategic plans, the acceptance of new products,the obsolescence of existing products, the resolution of potential patent issues,competition, changes in economic conditions, and other risks described in COTI’s publicdocuments such as press releases and filings with the Toronto Stock Exchange and theOntario Securities Commission.All forward-looking statements are qualified in their entirety by the cautionary statementsincluded in this document and such filings. These risks and uncertainties could cause actualresults to differ materially from results expressed or implied by forward-looking statementscontained in this presentation. These forward-looking statements speak only as of the dateof this presentation.Disclaimer
  10. 10. COTI-2 | A Potential BreakthroughTherapy for Many Cancers